Prenetics Launches ColoClear, a Non-Invasive Stool DNA Test to Detect Early Signs of Colorectal Cancer in Hong Kong harbourtimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from harbourtimes.com Daily Mail and Mail on Sunday newspapers.
- Clinical utility of 18F-fluciclovine being investigated in expanded areas of cancer imaging - Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization
Arquer Diagnostics ADXBLADDER Becomes First Bladder Cancer Urine Test To Undergo Rigorous Clinical Trials In USA
First patients recruited for bladder cancer recurrence monitoring study
News provided by
Share this article
SUNDERLAND, England, July 27, 2021 /PRNewswire/
ADXBLADDER has become the first new generation urinary biomarker test for bladder cancer to undergo rigorous clinical trials in the USA in decades. The innovative and highly accurate test, developed by UK company Arquer Diagnostics, is already approved for use across Europe.
ADXBLADDER is now being evaluated in a bladder cancer recurrence monitoring study in the US. With results of the study expected by the end of 2021, Arquer Diagnostics hopes to make a 510(k) premarket submission to the US Food and Drug Administration (FDA) to gain clearance from the organisation for
FinancialNewsMedia.com News Commentary PALM BEACH, Fla., June 3, 2021 /PRNewswire/ As the world has adapted to the initial phase of the global pandemic, and vaccines are being manufactured